Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging
2016-11-18
org.kosen.entty.User@350aa791
이병국(bevis)
분야
보건의료
개최일
2016
신청자
이병국(bevis)
개최장소
URL
행사&학회소개
1. Introduction
2. Hybridizationstrategies
2.1. Chemicalconjugation
2.2. Desolvation-chemicalcrosslinking
2.3. Insitucoating
2.4. Spray-drying
2.5. Proteintemplate-directedbiomimeticsynthesis
2.6. Miscellaneous
3. Drugloadingmechanisms
3.1. Covalentbonding
3.2. Physicalentrapment
3.2.1. Desolvation
3.2.2. Hydrophobicinteraction
3.2.3. Electrostaticattraction
3.2.4. Soaking
4. Impactsofproteinfunctionalization
4.1. Improvedbiocompatibilityandreducedtoxicity
4.1.1. Reducingthereleaseoffreemetalions
4.1.2. Hidingtheresidualtoxiccappingagents
4.1.3. Enhancingthewaterdispersibility
4.1.4. Reducingtheimmunotoxicity
4.1.5. Improvedrenalexcretion
4.1.6. Reducingthethrombogenicactivity
4.2. Prolongedcirculation
4.3. Improvedcolloidalstability
4.4. Alteredskinpermeation
4.5. Enhanced targeting efficiency
4.5.1. Smallmolecules
4.5.2. Antibodies
4.5.3. Peptides
5. Pharmaceuticalapplicationsofhybridprotein-inorganicnanoparticles
5.1. Combinatorialcancertherapy
5.1.1. Combinedchemotherapyandmagnetictargeting
5.1.2. Combinedchemotherapyandmagnetichyperthermia
5.1.3. Combinedchemotherapyandphotothermaltherapy(PTT)
5.1.4. Combinedchemotherapyandphotodynamictherapy
5.1.5. Combinedphotothermalandphotodynamictherapy
5.1.6. Combinednanophotothermolysisandproteintargeting
5.1.7. Combinedchemo-andradio-therapy
5.2. Cancerimaging
5.2.1. ImprovedMRcontrastimaging
5.2.2. Enhanced fluorescenceimaging
5.2.3. Dualimagingmodality
5.2.4. Multimodalimagingmodality
5.2.5. Blood-poolangiography
5.3. Cancernano-theranostics
5.4. Stimuli-responsivedrugrelease
5.4.1. Magneto-responsivedrugrelease
5.4.2. pH-responsivedrugrelease
5.4.3. Enzyme-responsivedrugrelease
5.4.4. Thermo-responsivedrugrelease
5.4.5. Multi-stimuli-responsivedrugrelease
6. Thephysicochemicalpropertiesofnanohybrids
6.1. Particlesize
6.2. Surfacecharge
7. Conclusions
References
2. Hybridizationstrategies
2.1. Chemicalconjugation
2.2. Desolvation-chemicalcrosslinking
2.3. Insitucoating
2.4. Spray-drying
2.5. Proteintemplate-directedbiomimeticsynthesis
2.6. Miscellaneous
3. Drugloadingmechanisms
3.1. Covalentbonding
3.2. Physicalentrapment
3.2.1. Desolvation
3.2.2. Hydrophobicinteraction
3.2.3. Electrostaticattraction
3.2.4. Soaking
4. Impactsofproteinfunctionalization
4.1. Improvedbiocompatibilityandreducedtoxicity
4.1.1. Reducingthereleaseoffreemetalions
4.1.2. Hidingtheresidualtoxiccappingagents
4.1.3. Enhancingthewaterdispersibility
4.1.4. Reducingtheimmunotoxicity
4.1.5. Improvedrenalexcretion
4.1.6. Reducingthethrombogenicactivity
4.2. Prolongedcirculation
4.3. Improvedcolloidalstability
4.4. Alteredskinpermeation
4.5. Enhanced targeting efficiency
4.5.1. Smallmolecules
4.5.2. Antibodies
4.5.3. Peptides
5. Pharmaceuticalapplicationsofhybridprotein-inorganicnanoparticles
5.1. Combinatorialcancertherapy
5.1.1. Combinedchemotherapyandmagnetictargeting
5.1.2. Combinedchemotherapyandmagnetichyperthermia
5.1.3. Combinedchemotherapyandphotothermaltherapy(PTT)
5.1.4. Combinedchemotherapyandphotodynamictherapy
5.1.5. Combinedphotothermalandphotodynamictherapy
5.1.6. Combinednanophotothermolysisandproteintargeting
5.1.7. Combinedchemo-andradio-therapy
5.2. Cancerimaging
5.2.1. ImprovedMRcontrastimaging
5.2.2. Enhanced fluorescenceimaging
5.2.3. Dualimagingmodality
5.2.4. Multimodalimagingmodality
5.2.5. Blood-poolangiography
5.3. Cancernano-theranostics
5.4. Stimuli-responsivedrugrelease
5.4.1. Magneto-responsivedrugrelease
5.4.2. pH-responsivedrugrelease
5.4.3. Enzyme-responsivedrugrelease
5.4.4. Thermo-responsivedrugrelease
5.4.5. Multi-stimuli-responsivedrugrelease
6. Thephysicochemicalpropertiesofnanohybrids
6.1. Particlesize
6.2. Surfacecharge
7. Conclusions
References
보고서작성신청
최근 항암제 전달과 이미징에 활용하기 위한 단백질-무기물 접합 나노입자 개발에 대한 관심이 높아지고 있습니다. 무기물질은 어떤 특성을 가지며 약물 전달과 이미징 활용에 어떤 기여를 할 수 있는지 논의 할 수 있는 자료 입니다. 또한 약물 전달과 이미징을 동시에 하는 theranostics (therapy + diagnostics)를 실현 하는데 많은 기여를 할 것으로 기대됩니다.